Stargazer Pharmaceuticals
An ophthalmic biotech company focused on the development of a novel treatment option for a genetic orphan retinal disease with significant unmet medical needs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
$57.0m | Series A | ||
| Total Funding | 000k | ||
Related Content
Stargazer Pharmaceuticals Inc is a biotech company specializing in ophthalmic treatments, particularly for Stargardt Disease, a rare genetic retinal disorder with significant unmet medical needs. The company operates in the biotechnology and pharmaceutical market, focusing on developing novel therapeutic solutions for eye diseases. Stargazer's core product, STG-001, is an indirect visual cycle modulator that reduces plasma concentrations of Retinol Binding Protein 4 (RBP4), thereby slowing down the visual cycle and accumulation of toxic retinoids in the eye. This innovative approach aims to provide a much-needed treatment option for patients suffering from Stargardt Disease.
Stargazer Pharmaceuticals primarily serves patients with rare ophthalmic conditions, working closely with healthcare providers and medical institutions. The company's business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary treatments. Revenue is generated through the sale of their therapeutic products, partnerships, and potential licensing agreements.
Keywords: Stargardt Disease, ophthalmic biotech, retinal disorder, visual cycle modulator, RBP4, retinoids, genetic disease, novel treatment, clinical trials, therapeutic solutions.